Pfizer shares climbed 11.43% over the past 30 days as investors reassess the company’s mRNA oncology pipeline. This momentum follows positive Phase 3 results from a competing melanoma treatment developed by Merck and Moderna.
The success of rival mRNA technology has revitalized sentiment across the cancer vaccine sector. This shift marks a strategic transition for Pfizer as it moves beyond its post-COVID focus.
Analysts are also tracking Pfizer’s obesity drug candidate, berobenatide, as a key catalyst for long-term growth. The company aims to use these developments to diversify revenue away from legacy products.